You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 292 No. 21, December 1, 2004 TABLE OF CONTENTS
  JAMA
  •  Online Features
  This Week in JAMA
 This Article
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

This Week in JAMA

JAMA. 2004;292:2547.

Rhabdomyolysis and Lipid-Lowering Drugs

Lipid-lowering agents such as fibrates and statins can have adverse effects on muscle, including rhabdomyolysis; however, reliable risk estimates for rhabdomyolysis are lacking. Graham and colleagues reviewed 1998-2001 pharmacy and hospital claims data and medical records for patients prescribed statins and fibrates, alone or in combination, to estimate the incidence of hospitalization for rhabdomyolysis. They found that rhabdomyolysis risk was low for monotherapy with atorvastatin, pravastatin, or simvastatin, but the risk increased for patients prescribed combined statin-fibrate therapy, particularly older patients with diabetes mellitus. Patients taking cerivastatin plus a fibrate had a 10% annual risk of rhabdomyolysis.

(SEE ARTICLE)


Thyroid Status in Old Age

The relationship of subclinical thyroid dysfunction to morbidity and mortality in older individuals is unclear. To assess the long-term impact of subclinical thyroid dysfunction on performance and survival, Gussekloo and colleagues (SEE ARTICLE) conducted a prospective, population-based study of persons aged 85 through 89 years in Leiden, the Netherlands. Comparing participants with subclinical or overt hypothyroidism at baseline with those having normal thyroid function, the authors found no differences in activity, depressive symptoms, or cognitive function. However, persons with increased thyrotropin levels had a lower risk of mortality over 3 years of follow-up. In an editorial, (SEE ARTICLE) Cooper discusses the implications of these findings for the care of elderly patients.


Thyroid Disease and Iodine 131 Exposure

Between 1944 and 1957, large amounts of sodium iodide 131 (131I) were released into the atmosphere near the Hanford Nuclear Site in Washington state, and there has been concern that exposed individuals may have an increased risk of thyroid disease. Davis and colleagues report results of a retrospective cohort study involving individuals born from 1940 through 1946, with presumed exposure to the Hanford 131I releases. In this cohort of individuals with low-dose and protracted environmental 131I exposure during infancy and childhood, the authors found no association of exposure with thyroid neoplasia, benign thyroid nodules, autoimmune thyroiditis, or hypothyroidism.



(SEE ARTICLE)


Pharmaceutical Postmarketing Surveillance

Recent reports of serious harms associated with approved medications have raised concerns about the drug approval and postmarketing surveillance systems and about potential conflicts of interest in the evaluation of adverse drug reactions. Several articles in this issue of JAMA explore these issues. Psaty and colleagues (SEE ARTICLE) report results of a literature review and related internal Bayer Corporation documents, which documented a clear and known association of cerivastatin with an increased risk of rhabdomyolysis. An article by Strom (SEE ARTICLE) discusses the role of voluntary adverse event reporting in monitoring drug safety and the limits of pharmacoepidemiologic analyses for triggering investigation of potentially serious events. Piorkowski, in an invited response, (SEE ARTICLE) describes Bayer Corporation’s premarketing and postmarketing knowledge of and response to reports of rhabdomyolysis related to cerivastatin use and critiques the assertions of Psaty and colleagues, (SEE ARTICLE) who provide a response to those critiques. In an editorial, (SEE ARTICLE) Fontanarosa, Rennie, and DeAngelis describe the circumstances surrounding this collection of articles and endorse measures to improve postmarketing drug surveillance and patient safety.


Medical News & Perspectives

A new initiative by the Centers for Disease Control and Prevention is designed to promote research into how to develop HIV/AIDS prevention strategies that are tailored to minority communities as well as to mentor young investigators with ties to these underserved communities.

(SEE ARTICLE)


Pruritic Eruption in HIV Infection

An altered and exaggerated immune response to arthropod bites may be the cause of a pruritic papular eruption common in persons with human immunodeficiency virus (HIV) infection in sub-Saharan Africa.



(SEE ARTICLE)


CLINICIAN'S CORNER
Thyroid Nodules

Clinical Crossroads
Mandel reviews the evaluation of a 64-year-old woman with a history of multinodular goiter and partial thyroidectomy who has a new thyroid nodule.



(SEE ARTICLE)


JAMA Patient Page

For your patients: Information about thyroid nodules.

(SEE ARTICLE)



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.